These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1343 related articles for article (PubMed ID: 27655849)

  • 21. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
    Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
    Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
    Linn YC; Hui KM
    Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expanded clinical-grade membrane-bound IL-21/4-1BBL NK cell products exhibit activity against acute myeloid leukemia in vivo.
    Zhao XY; Jiang Q; Jiang H; Hu LJ; Zhao T; Yu XX; Huang XJ
    Eur J Immunol; 2020 Sep; 50(9):1374-1385. PubMed ID: 32357256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined IL-15 and IL-12 drives the generation of CD34
    Cany J; van der Waart AB; Spanholtz J; Tordoir M; Jansen JH; van der Voort R; Schaap NM; Dolstra H
    Oncoimmunology; 2015 Jul; 4(7):e1017701. PubMed ID: 26140247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion.
    Khaznadar Z; Boissel N; Agaugué S; Henry G; Cheok M; Vignon M; Geromin D; Cayuela JM; Castaigne S; Pautas C; Raffoux E; Lachuer J; Sigaux F; Preudhomme C; Dombret H; Dulphy N; Toubert A
    J Immunol; 2015 Sep; 195(6):2580-90. PubMed ID: 26246143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Cytokine-Induced Memory-Like Natural Killer Cells.
    Berrien-Elliott MM; Wagner JA; Fehniger TA
    J Innate Immun; 2015; 7(6):563-71. PubMed ID: 25924651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
    Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
    Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
    Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
    Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
    Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
    Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive single-KIR
    Haroun-Izquierdo A; Vincenti M; Netskar H; van Ooijen H; Zhang B; Bendzick L; Kanaya M; Momayyezi P; Li S; Wiiger MT; Hoel HJ; Krokeide SZ; Kremer V; Tjonnfjord G; Berggren S; Wikström K; Blomberg P; Alici E; Felices M; Önfelt B; Höglund P; Valamehr B; Ljunggren HG; Björklund A; Hammer Q; Kveberg L; Cichocki F; Miller JS; Malmberg KJ; Sohlberg E
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapy.
    Arellano-Ballestero H; Zubiak A; Dally C; Orchard K; Alrubayyi A; Charalambous X; Michael M; Torrance R; Eales T; Das K; Tran MGB; Sabry M; Peppa D; Lowdell MW
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39032940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decitabine enhances targeting of AML cells by CD34
    Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
    Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia.
    Nuebling T; Schumacher CE; Hofmann M; Hagelstein I; Schmiedel BJ; Maurer S; Federmann B; Rothfelder K; Roerden M; Dörfel D; Schneider P; Jung G; Salih HR
    Cancer Immunol Res; 2018 Feb; 6(2):209-221. PubMed ID: 29321210
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
    Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
    Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
    Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant.
    Bednarski JJ; Zimmerman C; Berrien-Elliott MM; Foltz JA; Becker-Hapak M; Neal CC; Foster M; Schappe T; McClain E; Pence PP; Desai S; Kersting-Schadek S; Wong P; Russler-Germain DA; Fisk B; Lie WR; Eisele J; Hyde S; Bhatt ST; Griffith OL; Griffith M; Petti AA; Cashen AF; Fehniger TA
    Blood; 2022 Mar; 139(11):1670-1683. PubMed ID: 34871371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis.
    Venton G; Labiad Y; Colle J; Fino A; Afridi S; Torres M; Monteuil S; Loriod B; Fernandez-Nunez N; Farnault L; Suchon P; Mattei JC; Rihet P; Bergon A; Nguyen C; Baier C; Costello R
    Immunol Res; 2016 Dec; 64(5-6):1225-1236. PubMed ID: 27481509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-eminence and persistence of immature natural killer cells in acute myeloid leukemia patients in first complete remission.
    Dauguet N; Récher C; Demur C; Fournié JJ; Poupot M; Poupot R
    Am J Hematol; 2011 Feb; 86(2):209-13. PubMed ID: 21264910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 68.